Overview

First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy

Status:
RECRUITING
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
Induction phase of carboplatin+etoposide+pembrolizumab followed by maintenance of Pembrolizumab+sacituzumab govitecan
Phase:
PHASE2
Details
Lead Sponsor:
Nir Peled
Treatments:
Carboplatin
Etoposide
pembrolizumab
sacituzumab govitecan